抗体药物在肿瘤治疗中的应用与进展  

Recent Advances of Antibody Drugs in Tumor Therapy

作　　者：秦雨婷 泮明珠 张娟[1] QIN Yuting;PAN Mingzhu;ZHANG Juan(School of Life Science and Technology,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学生命科学与技术学院,江苏南京211198

出　　处：《药学进展》2024年第1期6-19,共14页Progress in Pharmaceutical Sciences

摘　　要：单克隆抗体药物以其特异性高、亲和力强、血清半衰期长等优点在肿瘤治疗领域得到广泛应用。基于母体单克隆抗体而设计的双特异性抗体、抗体片段、抗体药物偶联物等将抗体类药物的开发推至新的高潮。通过对抗体药物在肿瘤治疗领域的应用和最新进展、抗体药物的结构和作用机制进行介绍,并对肿瘤治疗抗体药物上市与临床开发现状进行总结,以期为抗体药物在肿瘤治疗领域的未来发展提供参考。Monoclonal antibody drugs have experienced rapid growth and shown remarkable performance in tumor therapy due to their high specificity,strong affinity and long serum half-life.Based on maternal monoclonal antibody,bispecific antibody,antibody fragments and antibody drug conjugates(ADCs)have pushed the development of novel antibody therapeutics to a new height.Here,we review the most recent advances in therapeutic antibodies for cancer treatment,outline various types of therapeutic antibodies and mechanisms of action,and summarize the current status of antibodies approved or under clinical development,aiming to provide some reference for future development of antibody drugs for cancer treatment.

关 键 词：肿瘤治疗 治疗性抗体 单克隆抗体 双特异性抗体 抗体药物偶联物 

分 类 号：R979.1[医药卫生—药品]